拉夏貝爾(06116.HK)涉及訴訟案件累計439起 累計索賠總額約15.32億元
格隆匯12月9日丨拉夏貝爾(06116.HK)公告,公司近期透過查詢國家企業信用信息公示系統及相關網站,獲悉公司若干附屬公司股權已被凍結。根據公司記錄,公司及其附屬公司涉及的訴訟案件的累計數目439起,累計訴訟中的索賠總額約人民幣15.32億元。於累計訴訟中,重大訴訟案件1起涉及訴訟金額約人民幣1.76億元;合共438宗訴訟累計涉及金額約人民幣13.47億元。
公司司法凍結資產的股權總值人民幣4.36億元,銀行賬户凍結數目85個;實際凍結金額總值約人民幣2.05億元,公司已查封房地產賬面值人民幣12.965億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.